Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disease in which a protein called alpha-synuclein builds up abnormally in brain cells, gradually destroying the systems that control movement, balance, blood pressure, bladder function, and more. It affects roughly two to five people per 100,000 worldwide, typically strikes in the mid-50s, and shortens life expectancy to about six to nine years from diagnosis. Because its early symptoms overlap heavily with Parkinson’s disease and other neurological conditions, MSA is frequently misdiagnosed, and no treatment yet slows or reverses the underlying damage. What follows is a practical walkthrough of what drives the disease, how it announces itself, and what can realistically be done about it.
What Happens Inside the Brain
The hallmark of MSA is the accumulation of misfolded alpha-synuclein protein inside a type of brain cell called an oligodendrocyte. Oligodendrocytes normally produce the insulating sheath around nerve fibers, so when they fill with clumps of this protein, the insulation degrades and nerve signaling breaks down. These protein clumps are called glial cytoplasmic inclusions (GCIs), and researchers have confirmed that they contain insoluble alpha-synuclein rather than the related beta or gamma forms of the protein.1PubMed. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein GCIs are found throughout the MSA brain, and their presence is what distinguishes MSA from other diseases involving alpha-synuclein, like Parkinson’s disease and dementia with Lewy bodies, where the protein accumulates mainly inside neurons rather than in the support cells around them.2Brain. Distinct ultrastructural phenotypes of glial and neuronal alpha-synuclein inclusions in multiple system atrophy
Why alpha-synuclein ends up in oligodendrocytes at all remains an open question. These cells do not normally produce much of the protein, so researchers have explored whether it might spread to them from neurons, or whether something goes wrong with the cells’ own protein-handling machinery.3PubMed Central. Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad The practical consequence is widespread white matter damage, meaning the wiring that connects brain regions degrades progressively. That is why MSA attacks so many systems at once rather than a single function.
Genetics, Environment, and Risk
MSA is not inherited in the straightforward way that some diseases are, but genetics does play a role. The most studied genetic link involves a gene called COQ2, which helps produce coenzyme Q10, a molecule critical for energy production in cells. A Japanese study published in the New England Journal of Medicine identified specific COQ2 mutations in families with multiple MSA cases and found that a common variant of the gene was also associated with sporadic (non-familial) MSA.4PubMed. Mutations in COQ2 in familial and sporadic multiple-system atrophy Subsequent research in European populations has been less clear-cut, but at least one additional COQ2 variant previously known to cause coenzyme Q10 deficiency has been found in an MSA patient, suggesting that carrying a single copy of certain COQ2 mutations could increase susceptibility.5PubMed Central. Analysis of COQ2 gene in multiple system atrophy
Environmental factors have also been investigated, though no single toxin or exposure has been definitively linked to MSA. Epidemiological studies have explored occupational exposures and lifestyle variables, but the rarity of the disease makes large-scale studies difficult to conduct.6PubMed Central. Multiple system atrophy: genetic or epigenetic? The current consensus treats MSA as a disease with complex origins: a combination of genetic susceptibility and unknown environmental triggers, rather than a purely genetic or purely environmental condition.
The Two Motor Subtypes
MSA is divided into two clinical subtypes depending on which set of motor symptoms dominates. MSA-P (parkinsonian type) features slowness, stiffness, and tremor resembling Parkinson’s disease. MSA-C (cerebellar type) is defined by problems with coordination and balance, including an unsteady gait, slurred speech, and difficulty with fine motor tasks like writing or buttoning a shirt.7PubMed Central. Multiple System Atrophy – Cerebellar Type: Clinical Picture and Treatment of an Often-Overlooked Disorder In practice, the two subtypes overlap considerably: about three-quarters of MSA-C patients also develop some parkinsonian features, and more than half of MSA-P patients develop cerebellar signs as the disease progresses.
Which subtype predominates depends partly on geography and ethnicity. MSA-P is more common in European and North American populations, accounting for roughly two-thirds to four-fifths of cases, while MSA-C predominates in Japanese, Korean, and Mestizo populations, where it represents 70 to 80 percent of cases.8PubMed Central. Multiple system atrophy Despite these different presentations, survival is similar between the two subtypes, averaging about eight to nine years from disease onset, with earlier onset (before age 55) predicting somewhat longer survival in both groups.9PubMed Central. Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival
The brain damage patterns are distinct between subtypes. In MSA-C, the cerebellum itself loses gray matter, and the white matter tracts running through the lower brainstem and cerebellum deteriorate. In MSA-P, the damage is predominantly in the white matter of the upper brain regions, without obvious gray matter loss on early imaging.10PubMed. Abnormalities of white and grey matter in early multiple system atrophy: comparison of parkinsonian and cerebellar variants
Autonomic Dysfunction
Autonomic failure is often the feature that most disrupts daily life, and it is a core part of MSA regardless of motor subtype. The autonomic nervous system regulates everything from blood pressure to bladder control to sweating, and MSA attacks it early and relentlessly. Cardiovascular problems are common, particularly orthostatic hypotension, a dangerous drop in blood pressure when standing that causes dizziness, lightheadedness, and fainting. Under recently updated diagnostic criteria, neurogenic orthostatic hypotension is identified in nearly two-thirds of MSA patients.11PubMed. Validation of Orthostatic Hypotension in MDS Diagnostic Criteria for Multiple System Atrophy
The severity of orthostatic hypotension matters for prognosis. One large study found that patients with severe orthostatic hypotension had a median survival of about 6.8 years, compared to roughly 8.1 years for those without it, and their risk of death was more than double.12PubMed Central. Orthostatic Hypertension in Multiple System Atrophy: Related Factors and Disease Prognosis Paradoxically, many patients also develop supine hypertension, meaning their blood pressure spikes dangerously when lying down. Managing both conditions in the same person is a constant balancing act.
Beyond blood pressure, autonomic dysfunction in MSA includes urinary problems such as overactive bladder and incomplete bladder emptying, constipation, delayed stomach emptying, and sexual dysfunction including erectile dysfunction in men and reduced sexual desire in both sexes.13Journal of Neurology. Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions Genitourinary symptoms can appear years before any motor problems, sometimes serving as the earliest detectable sign of the disease.
Respiratory Problems and Stridor
One of the more distinctive and dangerous features of MSA is laryngeal dysfunction, which can produce stridor, a high-pitched breathing sound caused by narrowing of the airway at the level of the vocal folds. This happens because the muscles that open the vocal folds during breathing stop working properly. Whether this is caused by actual paralysis of the nerve controlling those muscles, or by a dystonic pattern where the muscles that open and close the vocal folds fire simultaneously, is still debated.14PubMed Central. Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker? Some autopsy studies have found physical nerve damage, while others have not.
The practical concern is that stridor can cause sudden death during sleep, when muscle tone naturally drops and the already-compromised airway collapses further. For patients with stridor who have minimal daytime symptoms, continuous positive airway pressure (CPAP) or bilevel pressure machines can help keep the airway open at night. When airway obstruction is more severe, a tracheotomy may be necessary. Because MSA is progressive, patients who undergo tracheotomy are rarely able to have the tube removed.15JAMA Otolaryngology–Head & Neck Surgery. Bilateral Vocal Fold Paresis and Multiple System Atrophy
Cognitive and Psychiatric Features
MSA was traditionally considered a disease that spared thinking and memory, but that view has been revised. Research now shows that cognitive impairment is common, with executive dysfunction being the most frequent problem, affecting up to about half of patients. This manifests as difficulty with planning, problem-solving, mental flexibility, and generating word lists. Memory disturbances have been observed in up to two-thirds of patients, typically affecting the ability to learn and recall new verbal information.16PubMed Central. Cognitive impairment in multiple system atrophy: A position statement by the Neuropsychology Task Force of the MDS multiple system atrophy (MODIMSA) Study Group Language abilities tend to remain relatively intact, though this area has not been studied as thoroughly.
There may be cognitive differences between the two motor subtypes. A study of MSA patients in China found that those with the parkinsonian type had more severe impairments in visuospatial and executive functions, attention, language, and orientation compared to the cerebellar type.17Scientific Reports. A study on the characteristics of cognitive function in patients with multiple system atrophy in China This cognitive burden adds another layer of difficulty for patients and their families, on top of the physical symptoms.
How MSA Is Diagnosed
Diagnosis relies on a combination of clinical features and supportive evidence from brain imaging and, increasingly, laboratory biomarkers. No single test confirms MSA during life with certainty, and definitive diagnosis still technically requires autopsy. That said, certain imaging findings can strongly support the diagnosis.
For MSA-C, one of the most recognizable MRI findings is the “hot cross bun” sign, a cruciform pattern visible in the brainstem on certain MRI sequences. A multicentre study of autopsy-confirmed cases found that this sign, when clearly present within three years of motor symptom onset, had a specificity of nearly 98 percent for MSA-C. When combined with another signal change in the middle cerebellar peduncles, specificity reached 100 percent.18Journal of Neurology, Neurosurgery & Psychiatry. Revisiting ‘hot cross bun’ sign: a multicentre MRI study of 97 patients with autopsy-confirmed multiple system atrophy The sign is easier to detect on certain MRI sequences than standard ones, which has practical implications for how scans are ordered.19PubMed. Significance of the hot-cross bun sign on T2*-weighted MRI for the diagnosis of multiple system atrophy
Distinguishing MSA-P from Parkinson’s disease is harder, since both involve slowness and stiffness. Advanced imaging techniques that measure iron deposition in the putamen (a deep brain structure) can help, as iron levels tend to be higher in MSA-P than in Parkinson’s.20Parkinsonism & Related Disorders. Quantitative susceptibility mapping differentiates between parkinsonian disorders Patterns of brain tissue change in the basal ganglia also differ between MSA, Parkinson’s, and progressive supranuclear palsy, another disease it can be confused with.21NeuroImage. Differentiation of idiopathic Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging Brain volume measurements can add further evidence: in progressive supranuclear palsy, the thalamus tends to be smaller than in MSA-P, a clue that can be useful when these two conditions are in the differential.22PubMed. Patterns of brain atrophy in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy
Emerging Biomarkers
Beyond imaging, researchers are developing blood and body-fluid tests that may improve early and accurate diagnosis. Neurofilament light chain (NfL), a protein released when nerve fibers are damaged, rises significantly in the blood and cerebrospinal fluid of MSA patients, often even before the full clinical picture develops. In a study tracking patients who had early autonomic symptoms or REM sleep behavior disorder and later progressed to MSA, NfL levels were already elevated during the prodromal stage.23npj Parkinson’s Disease. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes
Another promising technique is the real-time quaking-induced conversion (RT-QuIC) assay, which detects the seeding activity of misfolded alpha-synuclein in body fluids. When applied to saliva samples, this test identified MSA in about 61 percent of confirmed cases, offering a non-invasive approach that could eventually complement existing diagnostic tools.24PubMed. Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson’s Disease and Multiple System Atrophy Sensitivity is not yet high enough for the test to stand alone, but combining it with NfL measurements and imaging could substantially narrow the diagnostic window.
Management of Motor Symptoms
Treating the motor problems in MSA is one of the most frustrating aspects of the disease. Levodopa, the cornerstone drug for Parkinson’s disease, produces a poor and often short-lived response in most MSA patients.25PubMed. Multiple system atrophy: an update Among those with MSA-P, an initial response to levodopa has been reported in about 15 out of 18 patients in one study, though this benefit tends to wane. By contrast, patients with MSA-C typically show no levodopa response at all.26Journal of Neurology, Neurosurgery & Psychiatry. Dystonia in multiple system atrophy When a trial of levodopa is attempted, the lack of sustained improvement is itself a diagnostic clue that the condition is MSA rather than Parkinson’s.
Because drug treatment for motor symptoms is limited, physical therapy becomes especially important. A prospective trial found that even a short course of physiotherapy improved gait performance in MSA-P patients, demonstrating that the approach is both feasible and safe in this population.27PubMed. Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial Occupational therapy focused on maintaining independence in daily activities, speech therapy for swallowing and communication difficulties, and assistive devices like walkers and wheelchairs all form part of the practical management toolkit.
Managing Autonomic Symptoms
While motor symptoms get much of the clinical attention, the autonomic problems often have a greater impact on quality of life and safety. Managing orthostatic hypotension, for example, involves a combination of non-drug strategies and medications. Compression garments, increased fluid and salt intake, sleeping with the head of the bed elevated, and rising slowly from sitting or lying positions are first-line measures. When these are not enough, medications that raise blood pressure can be added, though they must be used cautiously to avoid worsening the supine hypertension that many patients also have.13Journal of Neurology. Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions
Urinary problems are typically addressed with medications for bladder overactivity and, when incomplete emptying becomes an issue, intermittent catheterization. Constipation can be managed with dietary changes, stool softeners, and prokinetic agents. Each of these interventions targets a symptom rather than the disease itself, but collectively they can make a meaningful difference in daily comfort and safety.
Research Into Disease-Modifying Treatments
Because every current treatment is purely symptomatic, a great deal of research energy is directed at therapies that might slow or halt the underlying neurodegeneration. The most prominent targets involve alpha-synuclein itself. Therapeutic vaccines designed to provoke the immune system into producing antibodies against pathogenic forms of alpha-synuclein have reached early clinical trials. A phase 1 trial of two vaccine candidates, PD01A and PD03A, in early-stage MSA patients found both to be safe and well tolerated, and PD01A triggered a sustained antibody response targeting the alpha-synuclein epitope.28PubMed Central. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy Whether generating these antibodies actually slows disease progression is what later-phase trials must determine.
Other research directions include drugs that prevent alpha-synuclein from aggregating in the first place, antisense therapies that reduce production of the protein, stem cell therapies, and gene therapies.29PubMed Central. An update on multiple system atrophy The rarity of MSA makes clinical trials especially challenging to recruit for, but international collaboration among research centers has been increasing. There is cautious optimism that the growing understanding of alpha-synuclein biology will eventually translate into treatments that do more than manage symptoms.
Prognosis and Palliative Care
MSA progresses faster than Parkinson’s disease. Patients typically reach milestones like wheelchair dependence or frequent falls earlier in the disease course and live with these accumulating burdens for years.30Parkinsonism & Related Disorders. Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy The disease was historically known by several names depending on which symptoms predominated, including Shy-Drager syndrome, olivopontocerebellar atrophy, and striatonigral degeneration, before being unified under the MSA label in the 1990s.31PubMed. Multiple system atrophy: Building a global community – 30years of advocacy efforts
Palliative care is gaining recognition as a critical part of MSA management, not only in the final stages but integrated throughout the disease course. Because MSA simultaneously degrades mobility, autonomic function, speech, swallowing, and sometimes cognition, an interdisciplinary team that addresses comfort and quality of life from the outset can make a substantial difference.
The Burden on Caregivers
The rapid and unpredictable progression of MSA places an enormous strain on family caregivers. Qualitative research has found that caregivers struggle not just with the physical logistics of keeping their loved one safe and managing complex medication schedules, but also with the emotional weight of watching a progressive disease with no cure unfold.32Human Arenas. Multiple System Atrophy (MSA) and the Family Caregivers’ Burden: A Qualitative Study Communication difficulties caused by speech deterioration add frustration for both parties.
A mixed-methods study of MSA caregivers found that most experienced mild-to-moderate caregiver burden and mild anxiety, with the two strongly correlated. The rapid pace of disease progression was described as bewildering, and public home care services were cited as invaluable for keeping patients at home rather than in institutional settings. Caregivers also reported being inventive in finding sources of hope and quality of life despite the diagnosis.33PubMed. Multiple System Atrophy Caregivers’ Experience: A Mixed Methods Study Access to respite care, caregiver support groups (several now operate internationally through MSA advocacy organizations), and early involvement of social workers and palliative care teams can help families navigate what is an extraordinarily demanding caregiving experience.